Pharmacological and non-pharmacological treatments for major depressive disorder: Review of systematic reviews

BMJ Open

Volumn 7, Issue 6, 2017, Pages

  Gartlehner, Gerald ^a,b   Wagner, Gernot ^a   Matyas, Nina ^a   Titscher, Viktoria ^a   Greimel, Judith ^c   Lux, Linda ^b   Gaynes, Bradley N ^d   Viswanathan, Meera ^b   Patel, Sheila ^b   Lohr, Kathleen N ^b  

^a DANUBE UNIVERSITY KREMS   (Austria)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF HOHENHEIM   (Germany)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressants; cognitive behavioral therapy; complementary and alternative medicine; depression; exercise; psychological therapy; systematic review.

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ALTERNATIVE MEDICINE; COGNITIVE BEHAVIORAL THERAPY; DRUG EFFICACY; DRUG THERAPY; EXERCISE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ADULT; CLINICAL DECISION MAKING; COGNITIVE THERAPY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLINICAL DECISION-MAKING; COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85020550158     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-014912     Document Type: Review

References (56)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. VA: Arlington, American Psychiatric Publishing, 2013.
2. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-79.
3. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey replication (NCS-R). JAMA 2003;289:3095-105.
4. Fendrich M, Avci O, Johnson TP, et al. Depression, substance use and HIV risk in a probability sample of men who have sex with men. Addict Behav 2013;38:1715-8.
5. Silberbogen AK, Busby AK, Ulloa EW. Impact of psychological distress on prostate cancer screening in U.S. Military Veterans. Am J Mens Health 2014;8:399-408.
6. McLaughlin KA. The public health impact of Major depression: A call for interdisciplinary prevention efforts. Prev Sci 2011;12:361-71.
7. Farmer A, Korszun A, Owen MJ, et al. Medical disorders in people with recurrent depression. Br J Psychiatry 2008;192:351-5.
8. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-Analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7.
9. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013;34:119-38.
10. Mojtabai R, Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication. J Clin Psychiatry 2008;69:1064-74.
11. Qaseem A, Barry MJ, Kansagara D. Clinical Guidelines Committee of the American College of Physicians. nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;164:350-9.
12. Jobst A, Brakemeier EL, Buchheim A, et al. European Psychiatric Association guidance on psychotherapy in chronic depression across Europe. Eur Psychiatry 2016;33:18-36.
13. Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants : A systematic review and meta-Analysis. Drug Saf 2008;31:851-65.
14. Churchill R, Khaira M, Gretton V, et al. Treating depression in general practice: factors affecting patients' treatment preferences. Br J Gen Pract 2000;50:905-6.
15. van Schaik DJ, Klijn AF, van Hout HP, et al. Patients' preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry 2004;26:184-9.
16. Cooper LA, Gonzales JJ, Gallo JJ, et al. The acceptability of treatment for depression among African-American, hispanic, and white primary care patients. Med Care 2003;41:479-89.
17. Givens JL, Houston TK, Van Voorhees BW, et al. Ethnicity and preferences for depression treatment. Gen Hosp Psychiatry 2007;29:182-91.
18. Givens JL, Katz IR, Bellamy S, et al. Stigma and the acceptability of depression treatments among african americans and whites. J Gen Intern Med 2007;22:1292-7.
19. Nahin RL, Barnes PM, Strussman BJ. Expenditures on Complementary Health Approaches: United States. 2012. Atlanta GA: National Health Statistics Reports, 2016.
20. Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001;158:289-94.
21. Cochrane Depression, Anxiety, and Neurosis Group. CCDAN Topic list: intervention-Psychological therapies. London: The Cochrane Collaboration, 2013. http://cmd.cochrane.org/sites/cmd.cochrane.org/files/public/uploads/CCDAN%20topics%20list-psychological%20therapies%20for%20website-0.pdf. (accessed 5 Jul 2016)
22. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaboration, 2011.
23. Shojania KG, Sampson M, Ansari MT, et al. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 2007;147:224-33.
24. Jorm A, Allen N, Morgan A, et al. A guide to what works for depression. Melbourne: Beyondblue, 2013. http://resources. beyondblue. org. au/prism/file? token= BL/0556 . (accessed 22 Oct 2016)
25. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013-20.
26. Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011;64:1187-97.
27. Hedges LV. Distribution theory for Glass'sestimator of effect size and related estimators. Journal of Educational and Behavioral Statistics 1981;6:107-28.
28. Balshem H, Helfand M, Schönemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
29. Berkman ND, Lohr KN, Ansari MT, et al. Grading the strength of a body of evidence when assessing health care interventions: An EPC update. J Clin Epidemiol 2015;68:1312-24.
30. Yeung WF, Chung KF, Ng KY, Ky N, et al. A systematic review on the efficacy, safety and types of chinese herbal medicine for depression. J Psychiatr Res 2014;57:165-75.
31. Jun JH, Choi TY, Lee JA, et al. Herbal medicine (Gan Mai da Zao decoction) for depression: A systematic review and meta-Analysis of randomized controlled trials. Maturitas 2014;79:370-80.
32. Appleton KM, Sallis HM, Perry R, et al. Omega-3 fatty acids for depression in adults. The Cochrane Database of Systematic Reviews 2015;11:CD004692.
33. Sorbero ME, Reynolds K, Colaiaco B, et al; Acupuncture for major depressive disorder. A systematic review. Santa Monica, CA: RAND Corporation, 2015.
34. Linde K, Kriston L, Röcker G, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-Analysis. Ann Fam Med 2015;13:69-79.
35. Undurraga J, Baldessarini RJ, Randomized BRJ. Randomized, placebo-controlled trials of antidepressants for acute Major depression: Thirty-year meta-Analytic review. Neuropsychopharmacology 2012;37:851-64.
36. Josefsson T, Lindwall M, Archer T. Physical exercise intervention in depressive disorders: meta-Analysis and systematic review. Scand J Med Sci Sports 2014;24:259-72.
37. Liu X, Clark J, Siskind D, et al. A systematic review and metaanalysis of the effects of Qigong and Tai Chi for depressive symptoms. Complement Ther Med 2015;23:516-34.
38. Okumura Y, Ichikura K. Efficacy and acceptability of group cognitive behavioral therapy for depression: A systematic review and metaanalysis. J Affect Disord 2014;164:155-64.
39. Ekers D, Webster L, Van Straten A, et al. Behavioural activation for depression; an update of meta-Analysis of effectiveness and sub group analysis. PLoS One 2014;9:e100100.
40. Abbass AA, Kisely SR, Town JM, et al. Short-Term psychodynamic psychotherapies for common mental disorders. Cochrane Database Syst Rev 2014;7:CD004687.
41. Cuijpers P, Turner EH, Mohr DC, et al. Comparison of psychotherapies for adult depression to pill placebo control groups: A meta-Analysis. Psychol Med 2014;44:685-95.
42. van Marwijk H, Allick G, Wegman F, et al. Cochrane Database of Systematic Reviews 2012;7 http://onlinelibrary. wiley. com/doi/.
43. Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-Analysis of published and unpublished studies. BMJ 2014;348:g1888.
44. Gartlehner G, Gaynes B, Amick H, et al. Nonpharmacological versus pharmacological treatments for adult patients with major depressive disorder. Rockville, MD: 2015.
45. Al-Karawi D, Jubair L. Bright light therapy for nonseasonal depression: meta-Analysis of clinical trials. J Affect Disord 2016;198:64-71.
46. Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John's wort for major depressive disorder. Syst Rev 2016;5:148.
47. Furukawa TA, Weitz ES, Tanaka S, et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data meta-Analysis of pill-placebo-controlled trials. Br J Psychiatry 2017;210:190-6.
48. Galizia I, Oldani L, Macritchie K, et al. S-Adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev 2016;10:CD011286.
49. Sorbero ME, Reynolds K, Colaiaco B, et al. Acupuncture for major depressive disorder. A systematic review: RAND National Defense Research Institute, 2015.
50. Gartlehner G, Gaynes BN, Amick HR, et al. Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: An evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;164:331-41.
51. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
52. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: A meta-Analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45.
53. Furukawa TA, Cipriani A, Atkinson LZ, et al. Placebo response rates in antidepressant trials: A systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry 2016;3:1059-66.
54. Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-Analysis. BMJ 2015;351:h6019.
55. Loh A, Leonhart R, Wills CE, et al. The impact of patient participation on adherence and clinical outcome in primary care of depression. Patient Educ Couns 2007;65:69-78.
56. Melartin TK, Rytsälä HJ, Leskelä US, et al. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry 2005;66:220-7.